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An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to the gp120 V1/V2 region cor-
related inversely with infection risk. The RV144 protein immunogens (A244-rp120 andMN-rgp120) were modified by an N-ter-
minal 11-amino-acid deletion (11) and addition of a herpes simplex virus (HSV) gD protein-derived tag (gD). We investigated
the effects of these modifications on gp120 expression, antigenicity, and immunogenicity by comparing unmodified A244 gp120
with both11 deletion and gD tag and with11 only. Analysis of A244 gp120, with or without11 or gD, demonstrated that the
11 deletion, without the addition of gD, was sufficient for enhanced antigenicity to gp120 C1 region, conformational V2, and
V1/V2 gp120 conformational epitopes. RV144 vaccinee serum IgGs boundmore avidly to A244 gp12011 than to the unmodi-
fied gp120, and their binding was blocked by C1, V2, and V1/V2 antibodies. Rhesus macaques immunized with the three differ-
ent forms of A244 gp120 proteins gave similar levels of gp120 antibody titers, although higher antibody titers developed earlier
in A24411 gp120-immunized animals. Conformational V1/V2monoclonal antibodies (MAbs) gave significantly higher levels
of blocking of plasma IgG from A24411 gp120-immunized animals than IgG from animals immunized with unmodified A244
gp120, thus indicating a qualitative difference in the V1/V2 antibodies induced by A24411 gp120. These results demonstrate
that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and
immunogenicity.
The RV144 vaccine trial in Thailand demonstrated an estimatedvaccine efficacy of 31.2% in preventing HIV-1 acquisition in a
heterosexual population (1). A previous trial involving high-risk
intravenous drug users (IVDU) using AIDSVAX B/E (2–5) had
not shown protection (6, 7). The RV144 vaccine comprises a ca-
narypox ALVAC prime with the E.92TH023 gp120 membrane-
anchored insert and an AIDSVAX B/E gp120 boost. This vaccine
regimen induced Env antibody responses in 98.6% andCD4T cell
responses in 90.1% of vaccinated subjects (6) and induced tier 1
virus- but not tier 2 virus-neutralizing antibodies (1). The major-
ity of breakthrough infections in RV144 trial were subtype
CRF01_AE, (89% and 91.7% in the infected and placebo groups,
respectively) (6), suggesting that the immune responses elicited
against the clade E gp120 A244 Env protein were involved in low-
ering infection risk of HIV-1 acquisition.
The target of potentially protective or neutralizing antibodies
is the trimeric Env spike, which is sparsely present on HIV-1 viri-
ons (8, 9). Neutralizing epitopes presented on gp120 may be
masked by glycans, may be exposed only transiently following
receptor/coreceptor engagement, or may depend strongly on in-
tact quaternary structures (10–12). A major hurdle in HIV-1 Env
protein vaccine design is the preservation of the structural prop-
erties in soluble versions of Env proteins that mimic those on
intact viruses (13), particularly when the Env gp120 proteins are
expressed as monomers. Furthermore, the gp120 inner domains
and the coreceptor binding epitopes can be occluded in dimeric
(and probablymisfolded) forms of recombinant gp120, which are
often produced by mammalian cells together with gp120 mono-
mers (14). Thus, optimal presentation of neutralizing epitopes on
gp120 depends critically on its conformational state.
A number of conformational V2 antibodies that bind well to
epitopes on scaffolded murine leukemia viruses (gp70-V1/V2)
and to other recently described V1/V2 scaffold proteins have been
described (15–19). A clonal lineage of V1/V2 conformational
gp120 broadly neutralizing antibodies (bnAbs) CH01 to CH04,
which show blocking by the prototype V1/V2 conformational
gp120 monoclonal antibodies (MAbs) PG9 and PG16, bind to
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only a subset of gp120 monomers, including clade E.A244 gp120
(20). Although previously described as quaternary-structure-spe-
cific MAbs, with preferential binding to membrane-anchored tri-
meric HIV Env (21), PG9 and PG16 bnAbs can bind to mono-
meric and trimeric forms of some gp140 (22) and to rare
monomeric gp120 as well (20). The PG9 bnAb has been crystal-
lized bound to a V1/V2 scaffold protein and shown to bind pri-
marily to the V1/V2 C- strand and to adjacent glycans (17).
Thus, those V1/V2 conformational bnAbs for which PG9 is a pro-
totype bind to a conformational peptidoglycan epitope of gp120
V1/V2 (17). The RV144 Env, A244-rgp120 (20), a component of
AIDSVAX B/E (2, 5) is among the rare monomeric gp120s to
which the CH01-to-CH04 and PG9 antibodies bind. The unmu-
tated ancestor antibodies of the CH01-to-CH04 clonal lineage
also bindA244 gp120monomers, with an affinity within the range
appropriate for B-cell receptor triggering (20).
One unusual feature of the RV144 protein gp120 design was
that the proteins were constructed with a herpes simplex virus
(HSV) gD peptide tag and an 11-amino-acid (aa) deletion at the
gp120 N terminus (2, 5). Could features of the A244-rgp120 de-
sign have contributed to enhanced exposure of V1/V2 and V2
conformational epitopes on the vaccine proteins? If so, induction
of antibodies with specificity for the more prominently exposed
epitopes might be observed in RV144 vaccinees. A recently con-
ducted analysis of the RV144 case-control study showed that an-
tibody responses were to the C1, V2, V3, and C5 gp120 regions
and that high levels of IgG antibodies to a V1/V2 scaffold protein
correlated inversely with HIV-1 infection rate in vaccinees (23).
Thus, one hypothesis is that addition of the gD tag and/or the11
mutation provided enhanced presentation of certain gp120
epitopes and contributed to the induction of V1/V2 antibody re-
sponses in RV144-vaccinated subjects.
We report here that the RV144 gp120 protein immunogen,
A244-rgp120, was associated with enhanced antigenicity for C1,
V2, andV1/V2 conformational epitopes and that the gp120N-ter-
minal deletion (11) without inclusion of the HSV gD tag is suf-
ficient for enhanced antigenicity and immunogenicity in both hu-
mans and rhesus macaques.
MATERIALS AND METHODS
Proteins and antibodies. RV144 vaccine immunogen proteins (Table 1)
A244-rgp120 and MN-rgp120 were produced originally by Genentech,
Inc., further developed by VaxGen Inc., and supplied for this study by
GSID (Global Solutions for Infectious Diseases, South San Francisco,
CA). A244 gp120, A244 gD11, A24411, A244 gDN160K, MN gD11,
and MN gp120 were expressed in 293T cells (Table 1; Fig. 1) and lectin
affinity purified (24) followedby size exclusion chromatography (SEC) on
a Superdex 200 FPLC (GE Healthcare) to homogeneity for monomeric
gp120. Expression of additional gp120 proteins with N-terminal deletion
included the subtype B (63521 and 6240) and subtype C (C.089C and
C.1086) Env proteins described earlier (20, 25, 26). N-terminal deletion
for all Env gp120 involved 11 aa, except for C.1086, in which the corre-
sponding shorter N-terminal segment (7 aa) of the mature Env protein
was deleted. AE.A244 V1/V2 Tags and B.Case A2 V1/V2 Tags proteins
were constructed with an Ig leader sequence (METDTLLLWVLLLWVPG
STGD) as a protein cleavage and secretion signal at the N terminus and
Avi-tag followed by a His6 tag and were produced in 293F cells by trans-
fection and purified by nickel columns (H.-X. Liao, M. Bonsignori, S. M.
Alam, J. S.McLellan, G.D. Tomaras, andB. F.Haynes, unpublished data).
Synagis (palivizumab; MedImmune LLC, Gaithersburg, MD), a human
respiratory syncytial virus (RSV)MAb,was used as a negative control. The
C1 MAb A32, the V3 MAb 19b, and gp41 immunodominant MAb 7B2
were supplied by James Robinson (Tulane University, New Orleans, LA).
CH01 MAb as previously described was isolated, and its unmutated an-
cestor antibodies were inferred, from IgG memory B cells of a broad
neutralizer subject (20). Conformational V2 MAbs 697-D, 830A, 2158,
and 697-D Fab were provided by S.Z.-P. (New York University, NY) and
described previously (15, 27). V1/V2 conformational/quaternary MAbs
PG9 and PG16 were provided by Dennis Burton (IAVI and Scripps Re-
search Institute, La Jolla, CA), and the CD4 binding site MAb VRC01 was
from the Vaccine Research Institute, NIH (Bethesda, MD). CH58 MAb,
recently isolated from the plasma of an RV144 vaccinee by culturing and
screening of memory B cells, binds to the V1/V2 region of gp120 (Liao et
al., unpublished).
Surface plasmon resonance (SPR) kinetics and dissociation con-
stant (Kd) measurements. Env gp120 binding Kd and rate constant mea-
surements were carried out on BIAcore 3000 instruments using an anti-
human Ig Fc capture assay as described earlier (28–30). Anti-RSV Synagis
MAb was captured on the same sensor chip as a control surface. Nonspe-
cific binding of Env gp120 to the control surface and/or blank buffer flow
was subtracted for each MAb-gp120 binding interactions (see Fig. S1 in
the supplemental material). 697D Fab was directly coupled via amine
coupling chemistry to the sensor surfaces, Env gp120was flowed, and data
were collected as above. All curve fitting analyses were performed using
global fit of multiple titrations to the 1:1 Langmuir model. Binding of
697D and CH01 MAbs to A244 gp120 (unmodified) gave biphasic disso-
ciations, and the reported kd values are for the faster components of the fit.
Means and standard deviations (SD) of rate constants and Kd values were
calculated from at least threemeasurements on individual sensor surfaces
with equivalent amounts of captured antibody. All data analysis was per-
formed using the BIAevaluation 4.1 analysis software (GE Healthcare).
Isolation andpurificationof IgG fromplasma.Total IgGwas isolated
from individual RV144 vaccine recipient plasma samples using protein G
resin prepacked into 96-well depletion plates (GE Healthcare) as previ-
ously described (31). The sample volume was reduced to 50l by centrif-
ugation at 14,000  g in a microcentrifuge precooled to 4°C. A buffer
exchange was then performed using 2.5 volumes of phosphate-buff-
ered saline (PBS), pH 7.5. The concentrated IgG was diluted to the
desired volume with PBS and assayed for protein concentration using
a NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific) us-
ing the IgG reference setting.
Binding antibodymultiplex assays for anti-Env IgGwere performed as
previously described (32). Briefly, antibody measurements from vaccine
plasma (1:200 dilution) were acquired on a Bio-Plex instrument (Bio-
Rad), and the readout was expressed as mean fluorescent intensity (MFI)
TABLE 1 Env gp120 protein constructs used in the study
Env protein gD peptide
N-terminal
deletion size (aa)
A244-rgp120a  11
MN-rgp120a  11
A244 gp120 
A244 gD 11 gp120  11
A244 11 gp120  11
MN gp120 
MN gD 11 gp120  11
MN 11 gp120  11
92TH023 gp120 
92TH023 gD 11 gp120  11
63521 11 gp120  11
6240 11 gp120  11
1086 7 gp120b  7
a RV144 vaccine immunogen proteins A244-rgp120 and MN-rgp120 were produced by
Genentech Inc., developed by VaxGen Inc., and supplied by GSID.
b 1086 Env, in which the corresponding N-terminal segment (7 aa) is shorter, was
designed with 7 deletion.
Antigenicity of RV144 Vaccine Envelope Immunogen
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and concentration (g/ml) based on an HIVIG standard curve. Positive
and negative controls were included in each assay to ensure specificity and
for maintaining consistency and reproducibility between assays. To con-
trol for Env protein performance, the positive-control titer (HIVIG) in-
cluded on each assay had to be within3 SD of themean for each antigen
(tracked with a Levy-Jennings plot with preset acceptance of titer (calcu-
lated with a four-parameter logistic equation; SigmaPlot; Systat Soft-
ware).
SPR measurements of plasma IgG avidity. RV144 vaccine recipient
IgG avidity was measured on a BIAcore 4000 instrument (BIAcore/GE
Healthcare) using the multiplex array format (1 by 16) in which each IgG
sample was flowed over duplicate spots of 8 different Env gp120 antigen
surfaces, as described in the recent RV144 correlate analysis studies (23).
Antigen surface activity was monitored using the C1 MAb A32 as a posi-
tive control and an irrelevant anti-RSV (Synagis) MAb as a negative con-
trol (see Fig. S1 in the supplemental material). V1/V2 MAb CH01, which
is sensitive to N160K substitution, was used as a negative control for
antigen spots with A244gD/N160K gp120. An anti-gD Fab was used to
monitor binding to the gD peptide tag in Env gp120 with gD and to select
IgG samples with low gD reactivity for MAb blocking studies. The IgG
samples (n 97) from vaccinee plasma at week 26 (2 weeks following the
final immunization) and week 0 were diluted in PBS to 200 g/ml and
injected over each of the flow cells with replicate spots (2) at 10 l/min
for an association time of 120 s and a dissociation time of 600 s. A random
selection of IgG samples collected at visit 0 from 20 vaccinees was also
included. Each surface activity was monitored by including A32MAb (20
g/ml) injection every 20 cycles of IgG samples, and surface decay of A32
binding over the entire experimental run was used to normalize the bind-
ing signal of plasma IgG samples. Nonspecific binding of the negative-
control MAb was subtracted from each IgG sample binding data point.
Data analyses were performed with BIAevaluation 4000 and BIAevaluation
4.1 software (BIAcore/GE Healthcare) as described earlier for Biacore
3000 (29) and Biacore A100 (33) data analysis, respectively. Kinetic bind-
ing responses and dissociation rate constant (Kd) values (s
1) were mea-
sured usingmethods described earlier (23, 33) Themajority of IgG bound
with a relatively slow dissociation rate (	103 s1), and the previously
describedmethod for BIAcore A100 ranking of dissociation rates in com-
plex or polyclonal samples as a ratio of response units measured as bind-
ing late and stability late (33, 34) was modified to include binding re-
sponse and dissociation rate constant measurements as described earlier
(23, 35). A relative avidity binding score was calculated for each IgG sam-
ple as follows: avidity score  binding response/Kd, where the avidity
score is in RU · s, the binding response is in RU, and Kd is in s
1, with
higher binding responses and slower Kd being indicators of a higher-
affinity interaction (23, 35).
Antibody blocking assay.Antibody blocking using an enzyme-linked
immunosorbent assay (ELISA) was carried out as described earlier (30).
ELISA plates (384-well plates; Costar 3700) were coated with 30 ng/well
Env gp120 overnight at 4°C and blocked with assay diluent (PBS contain-
ing 4% [wt/vol] whey protein–15% normal goat serum–0.5%Tween 20–
0.05% sodium azide) for 1 h at room temperature. All assay steps were
conducted in assay diluent (except the substrate step) and incubated for 1
h at room temperature followed by washing with PBS–0.1% Tween 20.
Sera were diluted 1:50 and incubated in quadruplicate wells. For CD4
(binding site) blocking assays, 10 l of a saturating concentration of sol-
uble CD4 (Progenics Pharm Inc.) was added following the serum incuba-
tion step. Biotinylated target MAb (10 l) was added at the 50% effective
concentration (EC50) (determined by a direct binding of biotinylated
MAb to JRFL gp140). Values from quadruplicate wells were background
subtracted and averaged. Percent inhibition was calculated as follows: 100
 (sera triplicate mean/no inhibition control mean)100.
SPR antibody blocking using RV144 vaccinee IgG samples was mea-
sured on BIAcore 3000 instruments. Env immunogen A244 11 gp120
was immobilized on all flow cells of a CM5 sensor chip to about 5,000 to
6,000 RU using standard amine coupling chemistry. Blocking antibodies
were sequentially injected at predetermined concentrations to capture
near saturation. A zero baseline was set, and RV144 patient IgGs were
injected at 10 l/min for an association time of 180 s and a dissociation
time of 600 s. Kinetic binding responses were measured 15 s after the end
of the injection. The IgG samples (n 119) with high and midlevel bind-
ing (
80 RU) to A24411 gp120were selected from a panel of week 26 (2
weeks following the final immunization) plasma samples that included
infected vaccinee (n  41) and uninfected vaccinee (n  205) groups.
Randomly selected visit 0 vaccinee IgG samples (n 19) with no binding
to A24411 gp120 were included to assess nonspecific interactions. Anti-
gp41 MAb 7B2 was used as a negative-control blocking antibody. Test
antibodies included A32 (C1 region), PG9 and CH01 (V1/V2 conforma-
tional/quaternary), 2158, 697-30D and 830A (conformational V2),
and19b (V3)MAbs and the V2MAbCH58. Following each binding cycle,
surfaces were regenerated with a short injection (10 to 15 s) of either
glycine-HCl, pH 2.0, or 100 mM phosphoric acid. Blocking percentages
were calculated from the ratio of binding response after negative-control
7B2MAb blocking to the binding response after test antibody blocking:%
FIG 1 Diagram of HIV-1 gp120 proteins constructs with modifications. Designs for each of the A244 proteins either with no modifications (gp120), with both
the HSV gD tag (first 27 aa of mature HSV gD protein) andN-terminal 11-aa deletion (gD11 gp120), or with only the 11-aa deletion (11 gp120) are outlined.
The gD11 gp120 constructs for all three proteins are similar with respect to modifications to the design used in the RV144 vaccine trial for A244-rgp120 and
MN-rgp120. The Env gp120 proteins were expressed and purified as described inMaterials andMethods. A similar design was used to construct gp120 proteins
with orwithoutN-terminal deletion and included the clade BEnvMN, 63521, and 6240, the cladeC 1086, and the E clade 92TH023. LLE, linear linkage encoding.
Alam et al.
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blocking  [1  (RU after test MAb blocking/RU after control MAb
blocking)*100].
Isolation of antibodies fromRV144 vaccinee plasmamemory B cell.
Monoclonal antibodies CH51 and CH54 were isolated from circulating
IgGmemory B cells obtained from a vaccine recipient (subject 210884)
as previously described ((20). Briefly, CD2, CD14, CD16, CD235a,
IgD, and IgG cells were isolated from frozen peripheral blood mono-
nuclear cells (PBMCs) usingmagnetic activated cell sorting (Miltenyi Bio-
tec, Auburn, CA), and cultures were screened for binding to HIV-1 gp120
envelope glycoproteins contained in the vaccine formulation (36). Cells
from positive cultures were single-cell sorted, and PCR was performed as
previously described (37, 38). The supernatants were harvested from the
PCR-produced IgH and IgL gene expression cassette-transfected 293T
cells after 3 days of incubation at 37°C in 5% CO2, and the monoclonal
antibodies were purified as previously described (37).
NHP immunization. Two groups of three rhesus macaques were im-
munized by both intramuscular and nasal routes with either A244 gp120
(no modification) or A244 gD11 gp120 proteins. A third group of four
animals were similarly immunized with A244 11 gp120 proteins (with-
out gD). Animals in all three groups were immunized with 100 g of
gp120 monomeric proteins formulated in squalene and adjuvanted with
oCpG, R848, and MPL-A as described earlier (39, 40). The animals were
immunized at weeks 0, 4, 8, and 16, and plasma samples were collected at
time points corresponding to preimmunization (week 0) and at 2 weeks
following each immunization. Plasma antibody titers were measured by
binding ELISA to A244 gp120 and SPR blocking assay with conforma-
tional V2 and V1/V2MAbs as described above. For SPR blocking of non-
human primate (NHP) plasma IgG, biotin-labeled A244 V1/V2 Tags pro-
tein was captured on a streptavidin-coated CM5 (GE Healthcare) sensor
chip. As described above, each of the blocking MAbs and control MAbs
was bound to near saturation. Purified NHP plasma IgG (200 g/ml)
samples were then injected, and the binding levels of NHP IgG in the
presence and absence of blocking MAbs were calculated; the percent
blocking ofNHP IgGbinding by each of theV1/V2 (CH01 andCH58) and
V2 (697D) MAbs was calculated as described above for RV144 plasma
IgG, using the same formula, % blocking  [1  (RU after test MAb
blocking/RU after control MAb blocking)*100].
RESULTS
Expression of gp120 variants of the RV144 trial protein im-
munogens. To address the effect of the modifications on the
RV144 clinical trial protein Env gp120 antigenicity, we expressed
the immunogen proteins A244-rgp120 and MN-rgp120 in 293T
cells, with no modifications (A244 gp120 and MN gp120); with
only the 11-aaN-terminal deletion (A24411 gp120); or, as in the
RV144 Env immunogens, with both the HSV gD peptide tag and
the N-terminal deletion (A244 gD11 gp120 and MN gD11
gp120) (Fig. 1; Table 1). The E clade 92TH023 gp120 was also
expressed either with no modification (92TH023 gp120) or with
both the 11 deletion and the gD tag (92TH023 gD11 gp 120).
These Env proteins were compared for gp120 monomer expres-
sion and for their binding toMAbs that recognize conformational
epitopes on gp120.
Presentation of gp120 conformational epitopes on RV144
vaccine Env gp120 proteins with the gD tag and11 deletion. It
has been reported previously that one component of the RV144
Env immunogen, A244-rgp120, binds toMAbswith specificity for
the gp120 conformational V1/V2 epitopes (17, 20). The CH01 to
CH04 lineage V1/V2 bnAbs and PG9 bnAb bound to A244 gp120
withKd values ranging from 100 to 300 nM (20). Since PG9/PG16
MAbs bind preferentially to native trimers (21) and only to rare
gp120 monomers (20), the binding of PG9 and CH01 MAbs sug-
gests that the RV144 Env gp120 might show enhanced expression
of conformational epitopes in the V1/V2 loops.
We found that other conformational epitopes were also pre-
sented on both RV144 Env A244-rgp120 andMN-rgp120. In par-
ticular, the conformational V2 MAb 697-D, which fails to bind
linear V2 peptides (15), bound to MN- and A244-rgp120 with Kd
values of 477 nM and 318 nM, respectively (Fig. 2) The gp120 C1
MAb A32, which binds to the surface of transmitted/founder in-
fected CD4 T cells and mediates antibody-dependent cellular cy-
totoxicity (ADCC) (41), also bound strongly to the two RV144
Env gp120 proteins, with a relatively higher affinity for MN-
rgp120 (Fig. 2). The Kd of the V3 MAb 19b for MN-rgp120 was
about 5-fold lower than that of A244-rgp120 but was within the
range reported for other V3 MAb binding to Env gp120 proteins
(42). Thus, both of the RV144 vaccine gp120 immunogens ex-
pressed conformational epitopes within the C1, V2, and V1/V2
regions of gp120. The presentation of gp120 variable loop confor-
mational epitopes and the recent association of conformational
V2 antibodies with a lower rate of HIV-1 infection in RV144 (23)
raised the question as to whether one or both of the two RV144
vaccine Env modifications—inclusion of the HSV gD peptide tag
and/or theN-terminal11 deletion—might have led to enhanced
exposure of conformational epitopes within the C1 and V1/V2
regions.
The N-terminal 11-aa deletion (11) in A244 gp120 reduces
dimer formation. Expression of recombinant gp120 produces a
substantial amount of disulfide-linked gp120 dimer, in which
gp120 inner domain epitopes and the coreceptor binding surface
are occluded (14). To determine the effect the two modifications
on A244 gp120 might have on protein expression, we first com-
pared the oligomerization states of the three different A244 gp120
proteins. In reducing SDS-PAGE gel, A244 gp120 proteins mi-
grated as single bands of the expected size; under nonreducing
conditions, they gave a mixture of bands that corresponded
to monomers and dimers of gp120 (Fig. 3A). Size exclusion chro-
matography showed that A244 gp120 (Fig. 3B) had more dimer
(58% 1%) thanmonomer (38% 1%). In contrast, themono-
mer fraction of Env A244 11 gp120 was enriched almost 2-fold
(66% 1%), and the dimer fractionwas correspondingly reduced
(30% 1%;monomer-to-dimer ratio, 2.2:1 (Student’s t test, P	
0.001 formonomer fractions in A244 gp120 andA24411 gp120)
(Fig. 3C). The inclusion of the HSV gD peptide, in addition to the
11 modification, in A244 gD 11 (Fig. 3D) did not further im-
prove monomer enrichment, with a ratio of monomer to dimer
similar to that of A244 11 (63%  1% and 33%  1%, respec-
tively) (Student’s t test, P 0.11 for monomer fractions in A244
gD 11 and A244 11 gp120). The amount of higher-order oli-
gomers or aggregates was the same for all three expressed proteins
(about 3 to 4%) (Fig. 3). We observed a similar profile for the
92TH023 gp120 proteins, with a higher proportion of monomers
in 92TH023 gp120s with 11 and gD tag (65%) than without
any modifications (38%). MN gp120 expressed with 11 and
gD (MN gD gp120) or with no modifications (MN gp120) gave
similar proportions of dimers (34% and 31%, respectively). Ad-
ditional gp120 constructs derived from different clades including
clade B (63521 and 6240) and clade C (C.1086), designed to con-
tain their original signal peptide and deletion of the first 11 or 7
(C.1086) amino acid residues, were produced in 293 cells by tran-
sient transfection. For each of the above proteins, we found that
inclusion of 11 alone yielded predominantly monomers, as de-
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tected by SDS-PAGE under nonreducing conditions (data not
shown), and greater than 90%monomers in gel filtration chro-
matography analysis. Thus, the N-terminal 11 modification
alone resulted in markedly smaller amounts of gp120 dimer
formation when Env proteins were expressed in mammalian
cells.
Enhanced binding of conformational V2 antibodies and
V1/V2 bnAbs to A24411 gp120monomers.Monomers of each
of the A244 gp120 proteins (A224, A244 11, and A244 gD 11)
were purified to homogeneity by removal of dimeric and aggre-
gate fractions with size exclusion chromatography (SEC) (see Fig.
S2 in the supplemental material). Following SEC fractionation,
the monomeric gp120 proteins were stable and did not redistrib-
ute into dimer or aggregate fractions (see Fig. S2 in the supple-
mental material). Each of the three purified gp120 monomers
bound to CD4 and showed CD4-induced (CD4i) epitope upregu-
lation as assessed by 17b MAb binding (data not shown). A com-
parison of the binding of the size-fractionated monomeric and
dimeric A244 gp120 (data not shown) showed that the dimer frac-
tion had markedly reduced binding of the C1 MAb A32 and little
or no binding of the conformational V2MAb 697-D. This result is
consistent with previous reports (14) that the V1/V2 loop and the
N and C termini are involved in gp120 dimer formation and that
the epitopes on the Env inner domain are occluded in gp120
dimers.
Using a panel of antibodieswith specificities that included con-
formational C1, V2, and V1/V2 epitopes, we compared MAb
binding Kd and rate constants for each of the monomeric clade E
A244 gp120 proteins, to assess whether the11 and/or gD tag had
any effect on Env antigenicity (Fig. 4; Table 2). We observed that
inclusion of 11 had no effect on exposure of the V3 loop, since
the V3MAb 19b bound with similar Kd and kinetic rate constants
to each of A244 gp120 proteins (Table 2; Fig. 4A). The ADCC-
mediating, C1 MAb A32 (41), however, had a 9-fold- and 6-fold-
higher affinity for A244 11 and A244 gD 11, respectively, than
for A244 gp120 (Table 2; Fig. 4B). Similarly, the conformational
V2 MAb 697-D (15) had a nearly 10-fold-higher affinity for A244
gD 11 and A244 11 than for A244 gp120 (Kd  218, 157 and
1465 nM, respectively) (Fig. 4D; Table 2). We also observed these
differences using the Fab fragment of the V2 conformationalMAb
697-D, which bound to A244 gD 11 with 8-fold-higher affinity
than to unmodified A244 gp120 (see Fig. S3 in the supplemental
material; Kd 690 and 5,700 nM, respectively). While the disso-
ciation rate constants were similar, the ka (on-rate or association
rate constant) was nearly 10-fold higher for binding of 697-D to
A244 gD 11 than for binding to A244 gp120 (see Fig. S3 in the
supplementalmaterial).We also studied two other conformation-
dependent V2 MAbs, 2158 and 830A, which had higher affinities
for A244 gp120 than did 697-D (Table 2). Both had between 3-
and 5-fold-higher affinities for A244 gD11 and A24411 gp120
than for unmodified A244 gp120. Conformational V1/V2 bNab
CH01 showed a similar differential, while relatively smaller differ-
ences were observed with PG9 (Table 2). We conclude that the
epitopes recognized by conformational V2 and V1/V2 are well
exposed on A244 11 gp120.
These results suggest that the conformational V2 and V1/V2
FIG 2 Binding of C1, V2, and V3 antibodies to RV144 immunogen gp120 proteins. RV144 Env proteins MN-rgp120 and A244-rgp120 binding at various
concentrations (0.5, 1.0, 2.0, 3.0, 4.0, and 5g/ml for A32; 2.0, 5.0, 10, 20, 40, and 60g/ml and 5.0, 10.0, 25.0, 50.0, 75.0, and 100g/ml for 697DMAb binding
toMN gp120 and A244 gp120, respectively; and 0.5, 1.0, 2.0, 3.0, 4.0, and 5g/ml for 19b) to A32, 697D, and 19b are shown. The calculated Kd values and fitted
curves (black line) for each of the binding interactions are shown. Each MAb was captured on anti-Fc antibody immobilized surfaces, and gp120 monomeric
proteins were injected as analytes, as described in Materials and Methods. The data are representative of three measurements.
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epitopes recognized byMAbs 697-D and CH01 are better exposed
or conformationally more stable on A244 gp120 proteins with the
11 modification, with or without the inclusion of HSV gD, than
on the unmodified protein. In most cases, the differences in Kd
were due to differences in the association rates, ka, with roughly 5-
to 10-fold-higher rates of association with gp120 bearing a 11
modification for both 697-DFab andCH01MAb (Table 2; see Fig.
S3 in the supplemental material). The contribution of ka to the
differences in Kd supports the notion that exposure of particular
conformational epitopes is a critical factor in the enhanced anti-
genicity.
RV144 A244 11 Env binds well to CH01-CH04 clonal lin-
eage unmutated antibodies. Two unmutated ancestor antibodies
(UAs) of the MAb CH01 to CH04 clonal lineage, CH01_RUA1
andCH01_RUA2, have recently been shown to bind to the RV144
vaccine trial immunogen A244-rgp120 (20, 43). We compared
binding of the CH01-04 UAs to A244 11 gp120 with their bind-
ing to unmodified A244 gp120. CH01_RUA1 and CH01_RUA2
bound to A244 11 and A244 gD 11 gp120 with about 3- to
4-fold-higher affinity than to A244 gp120 (Fig. 5); the two CH01
UAs had roughly equivalent Kd values for the A244 gp12011
proteins. As observed for CH01 MAb, the binding association
rates of theUAs toA24411were greater than binding to unmod-
ified gp120; the dissociation rateswere similar (Fig. 5). The affinity
of the CH01-04 UAs for A24411 gp120 was lower, about 3-fold,
than was the affinity of the mature CH01 MAb; the effects of the
11 deletion were less pronounced for the UAs than for the CH01
mature antibody.
HSV gD and 11 modifications have smaller effects on the
antigenicity of B.MN gp120 and AE.92TH023 gp120. We next
compared the antigenicity of N-terminally deleted B.MN and
AE.92TH023 gp120 and a clade C gp120, C.1086, with their un-
modified counterparts (see Tables S1 and S2 in the supplemental
material). The N-terminal deletions had weaker effects on the an-
tigenicity of B.MN, AE.92TH023, and C.1086 gp120s than they
did for A244gp120 in particular, showing little or no effect on the
FIG 3 Relative proportions ofmonomer and dimer in A244 gp120 proteins. (A) SDS-PAGE analysis (under reduced and nonreduced conditions) of A244, A244
gD 11, and A244 11 gp120 proteins showing the presence of disulfide-linked dimers in various proportions. Each of the gp120 preparations was analyzed by
size exclusion chromatography (SEC), which showed a relatively larger proportion of monomer in A244 gp120 (B) than in either A24411 (C) or A244 gD11
(D). Peak volume analysis of themonomer and dimer fractions gave the following proportions ofmonomer and dimer: in A244 gp120-A244 gp120, dimer, 58%,
and monomer, 38%; in A244 11 gp120, dimer, 30%, and monomer, 66%; in A244 gD 11 gp120, dimer, 33%, and monomer, 63%. Similarly, for B.63521
gp120, the proportion of monomer was improved by N-terminal deletion: for 63521 gp120, dimer, 23%, andmonomer, 77%; and for B.6325111 gp120, there
was no resolved peak for the dimer and the result for monomer was
95%. For C.1086, a modest improvement was observed with C.1086 gp120 (dimer, 33%;
monomer, 67%) and C.10867 gp120 (dimer, 27%; monomer, 73%). The standard deviation of the measurements of percentage of monomer and dimer was
within 1%.
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FIG 4 Enhanced binding ofC1,V2, andV1/V2 antibodies to E.A244gp120 proteinswith11 deletion. Each of the analyte gp120 proteins (left panel, A244 gp120;
middle panel, A244gD11; right panel, A24411 gp120) was injected over the listed antibodies captured on an anti-Fc immobilized surface. Each gp120 protein
was titrated at 0.5, 1.0, 2.0, 3.0, 4.0, and 5.0g/ml for 19b (A) and A32 (B); A244 gp120 at 10, 20, 30, 40, and 50g/ml for 697D (C); 10, 25, 50, 75, and 100g/ml
on CH01(D) and PG9 (E); A244gD11 at 5, 10, 20, 30, and 40 g/ml for 697-D and 10, 25, 50, 75, and 100 g/ml for CH01 and at 10, 20, 30, and 40 g/ml for
PG9; A24411 at 2, 4, 6, 10, 25, and 50g/ml for 697-D, 10, 25, 50, 75, and 100g/ml for CH01 and 10, 25, 50, 75, and 100g/ml for PG9MAb captured surfaces.
Data are representative of at least 3 measurements made on individual flow cells with equivalent amounts of captured antibodies. All SPR binding experiments
were carried out using purified monomeric gp120 as assessed by size exclusion chromatography.
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binding of C1 or V1/V2 MAbs. However, there was 1 log more
avid binding of the CD4 binding site bnAb, VRC01, to MN11
gp120 than to MN gp120 (see Table S1 in the supplemental ma-
terial). Thus, the effects of N-terminal deletions on gp120 im-
munogens depend on the particular gp120 tested.
Plasma IgG from RV144 vaccinees binds with higher avidity
to A244 gD11 gp120.The effect of11modification in enhanc-
ing the antigenicity of gp120 conformational epitopes to C1, V2,
andV1/V2 raises the question as towhether antibodies induced by
the RV144 immunogen (A244 gD 11) also bind more avidly to
A244 11 than to A244 gp120. We purified IgGs from RV144
vaccinee plasma taken 2 weeks after the final ALVAC/AIDSVAX
B/E immunization (week 26) and measured their relative avidity
scores for each of the A244 gp120 proteins in an SPR binding
assay. Compared to placebo and prevaccination visit 1 IgG sam-
ples (no binding), IgG samples from the week 26 vaccinee group
bound A244 gD 11 gp120 with avidity scores that ranged over 2
orders of magnitude (Fig. 6A). The mean avidity for both A244
11 and A244 gD 11 were both significantly higher (P	 0.001)
than that for A244 gp120 (Fig. 6A). In theHIV-1 binding antibody
multiplex assay, we also found a significant difference; RV144
plasma IgG showed more avid binding to A244 11 gp120 than
did A244 gp120 (P 	 0.001; Fig. 6B). Thus, the RV144 vaccine
gave rise to antibodies with higher avidity for A244 gp120 with the
11 modification than for unmodified A244 gp120.
Conformational antibodies to C1, V2, and V1/V2 block
RV144-induced IgG binding to A244 11 gp120. To assess the
specificity of the antibodies induced by RV144 vaccine gp120 im-
munogens, we measured the relative level of blocking of vaccinee
IgG binding by a panel of MAbs, including those that showed
higher affinity for A24411 gp120. As shown in Fig. 6C, the bind-
ing of vaccinee IgG was blocked by each of the C1 (A32), V2
(697-D), and V1/V2 (CH01) bnAbs tested, with the strongest
blocking observed with A32 (67.4%). For the V2 epitope, we also
used two additional V2 MAbs, 2158 and 830A, which show vari-
ous levels of overlap; 830A strongly blocks all other V2MAbs (27)
(data not shown). Among the V2 MAbs, blocking of RV144 IgG
was strongerwith 697-D and 830A (see Fig. S4 in the supplemental
material), both of which had enhanced binding to A244 with 11
modifications (Table 2).
Of the two conformational V1/V2 gp120 bnAbs, we found no
blocking of RV144 IgG binding by PG9 (data not shown) but
detectable blocking (22.1%) by CH01 (Fig. 6C). We also deter-
mined blocking of plasma antibodies in ELISAs for antibodies that
inhibit binding of biotinylated MAb A32 and of soluble CD4. In
these assays, the mean blocking rates of A32 and sCD4 binding
were 39.6% and 13%, respectively (Fig. 6D).
These results suggest that the RV144 vaccine induced a rela-
tively larger proportion of antibodies directed against the confor-
mational C1 (A32) epitope, which is the target for ADCC in the
TABLE 2 Dissociation and kinetic rate constants of antibody binding to A244 gp120 proteinsa
Antibodyb
Rate constant and/or
Kd A244 gp120
A244 gD
11 gp120
E.A244 11
gp120
A32 ka ( 10
3 M1 s1) 76.8 11.4 134 14.0 222.6 20.4
(C1) kd ( 10
3 s1) 0.47 0.05 0.13 0.017 0.15 0.03
Kd (nM) 6.25 1.4 1.0 0.22 0.67 0.13
19b ka ( 10
3 M1 s1) 130.3 10.5 170.3 8.5 239.3 19.8
(V3) kd ( 10
3 s1) 1.54 0.095 1.4 0.08 1.56 0.08
Kd (nM) 11.8 0.21 8.24 0.23 6.54 0.38
697-D ka ( 10
3 M1s1) 4.9 1.1 24.9 5.6 26.75 0.71
(V2) kd ( 10
3 s1) 7.0 1.98 5.24 0.54 5.18 0.6
Kd (nM) 1,465.3 317 217.6 45.7 156.7 34.0
830A ka ( 10
3 M1 s1) 21.8 3.1 41.1 1.9 59.9 4.6
(V2) kd ( 10
3 s1) 0.22 0.06 0.07 0.003 0.088 0.01
Kd (nM) 10.2 3.6 1.7 0.16 1.56 0.09
2158 ka ( 10
3 M1 s1) 16.4 0.98 28.7 1.0 36.5 1.8
(V2) kd ( 10
3 s1) 0.19 0.04 0.10 0.03 0.13 0.04
Kd (nM) 11.2 1.6 3.7 0.9 3.68 1.1
CH01 ka ( 10
3 M1 s1) 3.73 1.6 37.2 15.1 49.0 5.4
(V1/V2) kd ( 10
3 s1) 4.38 0.52 9.9 2.8 15.6 1.5
Kd (nM) 1,639 601 277.8 42 317 31.9
CH01-04 UA1 (V1/V2) ka ( 10
3 M1 s1) 6.7 2.5 16.7 6.3 17.6 0.5
kd ( 10
3 s1) 21.5 0.6 19.2 1.3 18.8 0.5
Kd (nM) 3,500 1200 1,100 250 1,050 220
CH01-04 UA2 (V1/V2) ka ( 10
3 M1 s1) 4.4 2.3 20.8 10.1 27.3 11.4
kd ( 10
3 s1) 13.9 0.2 17.7 0.6 26.2 1.0
Kd (nM) 3,200 950 870 200 940 50
PG9 ka ( 10
3 M1 s1) 5.0 3.5 11.5 0.6 10.9 0.9
(V1/V2) kd ( 10
3 s1) 1.1 0.4 0.55 0.03 0.57 0.06
Kd (nM) 183 44.0 48.1 0.15 52.6 2.9
VRC01 ka ( 10
3 M1 s1) 17.6 0.52 13.3 0.57 9.7 0.43
(CD4 bs) kd ( 10
3 s1) 0.28 0.02 0.21 0.06 0.39 0.03
Kd (nM) 15.7 1.7 15.8 3.9 36.7 1.4
a Each of the rate constants and Kd values was derived from at least three measurements on individual flow cells of the same sensor chip or from binding data collected on different
sensor chips. The mean and SD of rate constants (ka and kd) and Kd values are reported for each antibody binding to the three different forms of monomeric E.A244 gp120 proteins.
b Parentheses indicate gp120 region recognized by the MAbs.
Antigenicity of RV144 Vaccine Envelope Immunogen
February 2013 Volume 87 Number 3 jvi.asm.org 1561
 
trial vaccine plasma (36). The next-largest population of antibod-
ies tested targeted the conformational V2 epitopes recognized by
the conformational MAb 697-D, followed by CH01-like bnAbs.
No PG9-like antibodies were detected.
Monoclonal antibodies from RV144 vaccinees recognize
epitopes enhanced on A24411 gp120monomers.Using previ-
ously described methodologies for isolating antibodies from
memory B cells (20), two IgG antibodies, CH51 and CH54, were
isolated from circulating IgG memory B cells of an RV144 vac-
cine recipient (subject 210884) (36). A32 blocked binding of both
CH51 and CH54, suggesting that RV144-derived MAbs bound to
epitopes that overlap the C1 conformational epitope of A32. The
overall Kd values of CH51 and CH54 MAbs for binding to
A244gD11 were higher than that of the C1MAb A32 (Fig. 4 and
7), but both of these RV144 MAbs bound to A244 gD 11 and
A24411 with a 1-order-of-magnitude-lower Kd than they did to
A244 gp120 (Fig. 7A and B). Thus, the RV144 vaccinee-derived
antibodies (CH51 and CH54) with A32-like specificity showed
tighter binding to A244 gp120 with the N-terminal deletion and
mirrored the overall enhanced avidity detected in RV144 plasma
samples with A244 gD 11.
A244 11 gp120 induces antibodies blocked by conforma-
tional V2 andV1/V2MAbs in nonhuman primates.One predic-
tion of the observed enhanced antigenicity of N-terminal deletion
in A244 11 gp120 would be that there would be qualitative dif-
ferences in the induced V2 or V1/V2 antibodies. This prediction is
based on the results described above that gp120 N-terminal dele-
tion alone enhances the affinity of selected conformational V2
(697-D) and V1/V2 (CH01) MAbs to recombinant A244 gp120
proteins. Moreover, since the RV144 immune correlates study
showed that conformational V2 antibody responses were associ-
ated with a lower rate of HIV-1 infection (23), we were interested
to determine whether the A244 11 gp120 would induce higher
levels of conformational V2 and V1/V2 antibodies than those in-
duced by A244 gp120 with no modification. Thus, to assess the
immunogenicity of each of the different forms of the A244 gp120
proteins, we immunized three groups of rhesus macaques with
either A244 gp120, A244 gD 11, or A244 11 gp120 proteins.
We first tested themagnitude of the antibody responses in each
of the immunogen groups against various proteins. For each of the
postimmunization plasma sample groups PI-2, PI-3, and PI-4
(samples harvested 2weeks after immunization timepoints of 4, 8,
and 16 weeks, respectively), the reactivity levels (50% effective
dilution [ED50]) against the RV144 immunogen protein A244 gD
11 were similar in all three immunogen groups (Fig. 8A). The
ED50 dilution titers were also similar for all three groups of NHP
plasmawhen binding to A244 gp120 either with or without N-ter-
minal deletion (data not shown). The NHP plasma samples gave
FIG 5 Binding of CH01_RUA1 and CH01_RUA2 to A24411 gp120. Each of the CH01 RUAs (RUA1 and RUA2 data are shown in top and bottom panels,
respectively) was captured as described in the legend for Fig. 4. Each of the three forms of A244 gp120 was flowed at concentrations of 10, 25, 50, 75, and 100
g/ml. Kinetic rate constants andKdwere derived as described inMaterials andMethods. Data are representative of at least 3 measurements made on individual
flow cells with equivalent amounts of captured antibodies.
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high background to the gp70 carrier protein when reactivity to
gp70 Case A2 V1/V2 protein (18), which was used in the RV144
correlate analysis (23), was studied. Therefore, to assess the reac-
tivity of NHP plasma antibodies to the gp120 Case A2 V1/V2
region, we used an alternate antigen design lacking the gp70 car-
rier, the B. Case A V1/V2 Tags protein. Using the B. Case A V1/V2
Tags protein, 5-fold-higher mean plasma antibody ED50 binding
values were observed at PI-2 in A244 11-immunized macaques
than in macaques immunized with A244 gp120 with no N-termi-
nal deletion (Fig. 8B). Thus, while the overall magnitude of the
antibody responses to gp120 was similar in animals immunized
with A244 gp120 with either no modification or with N-terminal
deletion, binding to the clade B Case A2 V1/V2 loop region was
enhanced 5-fold after two immunizations with A244 11 gp120.
We had earlier observed in RV144 IgG samples that the in-
duced antibodies were blocked by certain conformational V2 and
V1/V2 antibodies (Fig. 6C). Thus, we reasoned that while the
overall magnitude of gp120 antibody responses was similar in the
three NHP immunogen groups, the A24411 gp120 immunogen
might have induced qualitatively different antibodies in rhesus
FIG 6 RV144 vaccinee sera antibody responses. (A) RV144 vaccinee IgG binding to A244 gp120 proteins show higher avidity for A244 gp120 with 11. RV144
visit 8 (week 26, 2 weeks following the final immunization) IgG (n 97) binding was measured for A244 gp120, A244 gD 11, and A244 11 gp120 proteins.
Binding responses and dissociation rate constants for avidity score measurements were calculated as described in Materials and Methods. The mean avidity of
binding to A244 gp120, A244 gD11, and A24411 gp120 were 1.0 1.5, 10.0 0.5, and 5.7 0.7 RU · s ( 105), respectively. The differences in avidity were
significant for A244 gp120 versus A244gD11 (Student’s t test, P	 0.001) and A244 gp120 versus A24411 gp120 (Student’s t test, P	 0.001). The binding of
plasma IgG samples from the placebo group is shown as open circles. (B) RV144 vaccinee plasma IgG binding to A244 gp120 proteins show higher relative
binding to A244 gp120 with 11. RV144 visit 8 (week 26, 2 weeks following the final immunization) plasma antibody was measured against A244 gp120, A244
gD 11, and A244 11 gp120 proteins in a binding antibody multiplex assay, and the mean fluorescence intensity (MFI) values were plotted. The differences in
binding responses were significant for A244 gp120 versus A24411 gp120 (Student’s t test, P	 0.001). (C) Blocking of RV144 induced IgG binding to A244 gD
11 gp120 by conformational C1 (A32), V2 (697D), and V1/V2 (CH01) antibodies. RV144 IgG samples (n 109) with high levels (
80 RU measured at 200
g/ml) of binding to A24411 gp120 were selected for antibody blocking studies. A control group (n 19, open circles) showing no binding to A24411 gp120
was included to assess nonspecific signal in IgG samples. The mean blocking rates of RV144 plasma IgG by MAbs A32, 697-D, and CH01 were 67.4% 11.4%,
34.1% 14.5%, and 22.1% 12.5%, respectively. (D) ELISAs showing high levels of A32 blocking (mean 39.6% 19.2%) by RV144 IgG and low levels of
CD4 blocking antibodies (mean 13% 8.9%). Blocking of IgG from visit 1 were 6.7% 4.2% and 8.9% 7.6% for A32 and CD4, respectively.
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macaques compared to those immunized with A244 gp120 with
nomodification. Therefore, we compared the levels of blocking by
conformational V2 and V1/V2 MAbs of purified plasma IgG har-
vested from animals in each of the NHP immunogen groups.
Blocking of binding toA244V1/V2proteinwas testedwithV2 and
V1/V2 mabs (Fig. 8C) at the time of peak gp120 responses (PI-3
IgG samples). Blocking by the conformational V1/V2 bNAb
CH01 was significantly higher (
2-fold-higher median values) in
the A244 11 animals (45.2%  7.2%) than in either those im-
munized with A244 gp120 with no modification (20.3% 3.8%;
P  0.006) or those with A244 gp120 with both 11 and gD tag
(18.7%  8.1%; P  0.026) (Fig. 8C). Similarly, for the confor-
mational V2MAb697-D, the observed blockingwas higher for the
A244 11 gp120 immunogen group (56.6% 9.8%) than for the
A244 gp120 (30.9% 4.2%; P 0.013 for A24411 versus A244
gp120) immunogen group. Blocking with the RV144 CH58MAb,
which binds a distinct V2 linear epitope (Liao et al., unpublished),
gave much higher blocking overall, but there were no significant
differences between the IgG samples from the three immunogen
groups (Fig. 8C).
These results suggest that while all three forms of A244 gp120
proteins induce an overall similar magnitude of gp120 antibodies,
inclusion of N-terminal deletion alone allowed the induction of
antibodies that were qualitatively different; a higher proportion of
V1/V2 antibody responses that were specifically blocked by the
conformational V2 and V1/V2 MAbs were induced.
DISCUSSION
The RV144 trial showed the estimated vaccine efficacy to be
31.2%. Future HIV-1 vaccine efficacy trials will therefore require
an improved immunogen design, and analysis of the RV144 im-
munogens is an important first step. In this work, we have probed
the effects of gp120 design on antigenicity and immunogenicity of
the immunogens used in the RV144 HIV-1 vaccine efficacy trial.
We have demonstrated that deletion of theN-terminal amino acid
residues of A244 gp120, which was used as boosts in the trial,
enhanced the antigenicity of gp120 conformational epitopes. The
enhanced epitopes were immunogenic in RV144 vaccinees, and
they induced immune responses with higher avidity for these con-
formational epitopes than for the same epitopes on the unmodi-
fied immunogen A244 gp120. We have also shown that an HSV
gD tag, introduced into the AIDSVAX B/E rgp120 as part of early
expression and purification strategies (5), did not contribute to
the antigenicity enhancement. Antigenic enhancement by the N-
terminal deletion 11 was more pronounced with A244 (clade E)
than with MN (clade B), 92TH023 (clade E), or 1086 (clade C)
gp120 proteins, suggesting that these effects may depend on the
particular gp120 vaccine immunogen. Finally, we demonstrated
that the N-terminal deleted gp120 A244 protein induced signifi-
cantly higher levels of macaque plasma antibodies that could be
blocked by conformational V2 MAbs compared to intact A244
gp120.
The higher proportion of disulfide-linked dimers in the prep-
arations of unmodified A244 rgp120 than in those with a 11
deletion (with or without the gD tag replacement) suggested that
the principal effect of removing theN-terminal residuesmay be to
enhance the reliability of folding in the endoplasmic reticulum.
Correctly folded gp120 has no unpaired cysteines, and any inter-
chain disulfides must form at the expense of correct intrachain
pairings. That is, at least part of the protein must be misfolded for
disulfide-linked dimers to form at all. Even the monomeric pro-
tein in any preparation may be conformationally heterogeneous;
the proportion of dimer will tend to reflect the degree of misfold-
ing within themonomer population. Because the consequences of
the N-terminal deletion depend on the rest of the gp120 se-
quence—it had a less marked effect on rgp120 from other iso-
lates—its influence on folding is Env dependent. Thus, we ob-
served marked improvement in purification of gp120 monomers
FIG 7 RV144 MAbs CH51 and CH54 show higher-affinity binding to A244gp120 with 11 modification. A244, A244 gD 11, and A244 11 gp120 were
each injected at increasing concentrations of 5, 10, 15, 20, and 25 g/ml over either CH51 (A) or CH54 (B) captured on anti-Fc immobilized surfaces.
Binding of both CH51 and CH54 was 1 order of magnitude higher for both A244 gp120 with the 11 modification than for A244 gp120 (left panel) with
no modification.
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on certain Envs, like E.A244 gp120 and B.63521, and amoremod-
est improvement in the case of C.1086 gp120.
Two observations show that the upregulation of conforma-
tional C1, V2, and V1/V2 epitopes on A244 gp120 was relevant to
the antibody responses induced in the RV144 trial. First, using
ELISA and SPR blocking assays, we have identified RV144 vac-
cinee antibodies that react with epitopes related to those recog-
nized byMAbs A32 (C1), 697-D (conformational V2), and CH01
(conformational V1/V2), and we have isolated from RV144 vac-
cinees human MAbs that are blocked in their binding to A244
gp120 by MAb A32 (44, 45). Moreover, MAb 697-D, which binds
to A244 gp120 and the gp70V1/V2 Case A2 clade B scaffolded
protein, binds to A24411 gp120 nearly 10-foldmore avidly than
it does to A244 gp120 with no modifications. Second, the RV144-
induced plasma antibody response had a higher avidity for A244
Envs with gD 11 or with 11 alone than for their unmodified
counterparts (Fig. 6). The conformational V2 and V1/V2 epitope
specificities induced by the vaccine included those that could be
blocked byMAbs CH01 and 697D, but not byMAb PG9 (Fig. 6C;
see also Fig. S4 in the supplemental material). Although we have
not yet been able to rescue a V2 MAb against the conformational
V2 or V1/V2 epitopes selectively recognized by 697-D or CH01,
we have demonstrated the presence of plasma antibodies with
specificities capable of blocking the binding of these MAbs to
A244 gp120 (Fig. 6C). Both the A244 gp120 MAbs isolated from
RV144 vaccinees (CH51 andCH54) boundA244 andMNgp120s,
their binding was blocked by A32, and both mediated antibody-
dependent cellular cytotoxicity (ADCC) toHIV-1AE_01-infected
CD4 T cell targets (36). Binding of both of these A32-like MAbs
(CH51 and CH54) to A244 gp120 was enhanced when the 11
deletion was introduced. These data strongly suggest that the ob-
served 11-enhanced gp120 antigenicity of RV144 gp120 im-
munogens played a role in the induction of certain antibody types
(C1, V2, and V1/V2) in the RV144 vaccinees.
Finally, the effect of11modification in enhancing the immu-
nogenicity of E.A244 gp120 was also supported by immunization
FIG 8 Higher levels of V1/V2 MAb blocking antibodies induced in rhesus macaques immunized with A244 11 gp120 protein. Binding ELISA titers (ED50,
half-maximal dilution titer) of NHP plasma antibodies to RV144 immunogen protein A244 gD11 gp120 (A) and the V1/V2 protein B. Case A V1/V2 Tags (B)
were measured for each animal in the three immunogen groups. Data from A244 gp120-, A244 gD 11 gp120-, and A244 11 gp120-immunized animals are
shown in open circles, filled circles, and filled diamonds, respectively. Bars in each plot indicate mean values for each of the indicated immunogen group. PI-2,
PI-3, and PI-4 indicate postimmunization plasma samples harvested 2 weeks after immunization time points of 4, 8, and 16 weeks, respectively. The difference
in titers between animal groups immunized with A244 gp120 (median ED50 342 125) versus A24411 gp120 (median ED50 1,069 583) for binding to
B. Case V1/V2 Tags did not reach statistical significance (P 0.09). (C) Blocking of NHP IgG with conformational V2 and V1/V2 MAbs. For 697-D blocking,
the median values ( SD) for A244 gp120-, A244 gD11-, and A24411 gp120-immunized NHP groups were 30.9 4.2 (28.7), 37.0 9.8 (33.6), and 56.6
9.8 (51.7), respectively (*, P  0.013 for A244 11 versus A244 gp120). For CH01 blocking, the blocking rates were 20.3%  3.8% (24.1%), 18.6%  8.1%
(21.8%), and 45.2% 7.4% (51.7%), respectively (*, P 0.006 for A24411 versus A244 gp120; **, P 0.026 for A24411 versus A244 gD gp120). For CH58,
the blocking rates were 77.5%  9.4%, 90.5%  4.6%, and 74.1%  24.3%, respectively, for A244 gp120-, A244 gD11-, and A244 11 gp120-immunized
groups. The median values in a second independent experiment were similar and are given in parentheses above. The measurement of blocking antibodies was
carried out on NHP IgG samples harvested from PI-3 plasma of each immunogen group and was performed as described for data in Fig. 6 and in Materials and
Methods.
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data from rhesus macaques showing a significantly higher level of
plasma antibodies that could be blocked by conformational V2
MAbs induced in animals immunized with A244 gp12011 than
the level found in the group immunized with A244 gp120 with no
modification (Fig. 8).
The underlying mechanism of protection in the RV144 trial
has yet to be elucidated—the immune correlates study has so far
identified only antibody responses that correlate directly (plasma
HIV-1 Env IgA) or inversely (plasmaAbs binding to gp70-V1/V2)
with infection risk (23). Subsequent studies are required to deter-
mine if these antibody types are causal correlates or are surrogate
markers of other factors.
In summary, we have shown that the 11 N-terminal deletion
on the gp120 Envs used in the AIDSVAX B/E boost of the RV144
HIV-1 vaccine trial enhanced gp120 epitope expression and aug-
mented both antigenicity and immunogenicity for the V2 and
V1/V2 gp120 regions. The 11 deletion (with or without gD) in
A244 gp120 leads to expression of a higher proportion of correctly
folded recombinant protein, and the stability and conformational
homogeneity of the immunogen are likely to have contributed
substantially to its properties. Our data suggest that careful atten-
tion to Env conformations and antigenicity will be critical when
designing immunogens in future trials.
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Figure S1. SPR binding curves showing specific and non-specific signal of gp120 protein 
binding to test and control antibodies.  
 
Figure S2. Size exclusion chromatography showing removal of gp120 dimers from Env 
proteins.  
 
Figure S3. Measurement of Dissociation constant (Kd) of binding of 697-D Fab fragment to 
A244 gp120 (unmodified) and A244 D11 gp120.   
 
Figure S4.  Blocking of RV144 vaccinee derived IgG binding to A244gDD11 gp120 by a panel 
of antibodies that target distinct epitopes on gp120.  
  
Table S1. Comparison of mAb binding Kd to B.MN and AE.92TH023 gp120 proteins with and 
without N-terminus deletion. 
 
Table S2. Comparison of antigenicity of C.1086 gp120 constructs with or without N-terminus 
deletion.    
 
 
 
 
 
0 
50 
100 
150 
200 
250 
300 
-50 0 100 200 300 400 500 600 
R
e
s
p
o
n
s
e
 (
R
U
) 
Time (s) 
E.A244 gDΔ11 [120 μg/mL] 
Synagis 
CH01 
697-30D  
PG9 
0 
50 
100 
150 
200 
250 
300 
-50 0 100 200 300 400 500 600 
R
e
s
p
o
n
s
e
 (
R
U
) 
Time (s) 
E.A244 gDΔ11 [120 μg/mL] 
Reference Subtracted 
Synagis 
CH01 
697-30D  
PG9 
0 
100 
200 
300 
400 
500 
600 
700 
800 
-50 0 100 200 300 400 500 600 
R
e
s
p
o
n
s
e
 (
R
U
) 
Time (s) 
E.A244 Δ11 [50 µg/mL] 
Synagis 
A32 
697-30D  
19b 
0 
100 
200 
300 
400 
500 
600 
700 
800 
-50 0 100 200 300 400 500 600 
R
e
s
p
o
n
s
e
 (
R
U
) 
Time (s) 
E.A244 Δ11 [50 ug/mL] 
Reference Subtracted 
Synagis 
A32 
697-30D  
19b 
Supplementary Figure S1. Both specific and non-specific signal for binding to A244 D11 gp120 to the listed 
mAbs are shown in the left panel. In the right panel, specific binding signal for each of the mAbs are shown following 
subtraction of non-specific signal on the control mAb, Synagis. Each mAb was captured on an anti-Fc immobilized 
surface as described in Methods.    
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Supplementary Figure S2. Size exclusion chromatography (SEC) showing  complete removal of dimer and aggregates 
and fractionation of a homogenous monomeric gp120 peak. SEC was performed on a Superdex S200 column and as 
decribed in Methods.   
Supplementary Figure S3. 697D Fab binds to A244 gp120 with D11 with higher affinity. 697-D Fab was 
directly immobilized using amine coupling on a CM5 sensor chip and as previously described (Alam et 
al., 2007). A244 gp120 proteins were injected at concentrations ranging from 5 -200 ug/mL.  
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Supplementary Figure S4. Blocking of RV144 induced IgG binding to A244gDD11 gp120 by C1 (A32), V2 
(697D, 830A, 2158), V3 (19b), VRC01 (CD4 bs) and V1/V2 (CH01, PG9) antibodies. RV144 IgG samples 
showing blocking of binding to A244D11 gp120 by two of the conformational V2 mAbs 830A and 697D but not by the 
V2 mAb 2158.  Data shows mean and std. error of blocking of RV144 visit 8 IgG samples binding to A244 gDD11 gp120 
by A32 (n=25); PG9 (n=16); CH01 (n=25); V2 mAbs (n=25 for 697D; n=18 for 2158); 19b (n=25) and VRC01 (n=25).  
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Supplementary Table 1. Effect of gD, D11 design on B. MN and AE. 92TH023 
gp120 Epitope Expression 
Antibody
/Epitope 
MN D11 
gp120 
 
MN gD D11 
gp120 
MN  
gp120 
92TH023 
gD D11 
gp120 
92TH023 
gp120 
A32 (C1) 0.3 1.2 0.61 2.2 6.1 
19b (V3) 1.4 1.7 1.6 3.3 3.1 
VRC01 
(CD4 bs) 
0.2 1.4 4.4 21.0 31.3 
697D 
(V2) 
141 440 1064 277 550 
PG9 
(V1/V2) 
114 140 206 155 184 
Dissociation Constant, Kd (nM) 
The Kd values are representative of at least three measurements for each of the mAb binding to gp120 proteins with either gDD11 
modifications or with no modifications. Kd values were determined by SPR measurements and the SPR assay is described in the 
Methods section of the main text of the manuscript. 
Antibody/Epitope 1086c 
gp120 
1086c gD 
gp120 
1086c D7 
gp120 
CD4 25.8 24.5  27.9  
17b (CD4i) 1.7  1.35  1.5  
A32 (C1) 4.2  4.1  2.2  
VRCO1 (CD4 bs) 18.7  17.0  17.3  
19b (V3) 15.5  16.3  19.0  
697-30D (V2) 619  321  425  
2158 (V2) 16.2 16.7  19.5  
830A (V2) 8.9  16.0  10.1 
PG9 (V1/V2) -  - - 
PG16 (V1/V2) - - - 
CH01 (V1/V2) - - - 
2G12 (-CHO) 34  46.7  25.2  
Supplementary Table 2. Antigenicity of Clade C 1086 gp120  with gD and N-terminus  deletion 
The Kd values are representative of at least three measurements for each of the mAb binding to gp120 proteins with either gDD7 or D7 
modifications or with no modifications. - = no binding. 
Dissociation Constant, Kd (nM) 
